Transformants (e.g., Recombinant Dna Or Vector Or Foreign Or Exogenous Gene Containing, Fused Bacteria, Etc.) Patents (Class 435/252.3)
  • Patent number: 10385375
    Abstract: The present invention relates to a method for preparing 7-dehydrocholesterol and/or the biosynthetic intermediates and/or secondary products thereof by culturing organisms, in particular yeasts. Furthermore, the invention relates to the preparation of the nucleic acid constructs required for preparing the genetically modified organisms and to said genetically modified organisms, in particular yeasts, themselves.
    Type: Grant
    Filed: January 23, 2017
    Date of Patent: August 20, 2019
    Assignee: Novozymes A/S
    Inventors: Christine Lang, Markus Veen
  • Patent number: 10370692
    Abstract: Herein is reported a method for producing a fusion-polypeptide comprising the steps of a) cultivating a mammalian cell comprising a nucleic acid encoding a variant fusion-polypeptide wherein the amino acid sequence of the fusion-polypeptide has been modified by replacing in a pro-fusion-polypeptide the endogenous protease cleavage site between the pro-peptide and the fusion-polypeptide with an exogenous (with respect to the origins of the parts of the fusion-polypeptide) or artificial protease cleavage site, and b) recovering the fusion-polypeptide or fusion-pro-polypeptide from the cell or the cultivation medium and thereby producing the (recombinant) fusion-polypeptide.
    Type: Grant
    Filed: December 10, 2014
    Date of Patent: August 6, 2019
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Erhard Kopetzki, Jens Niewoehner, Peter Maier
  • Patent number: 10370422
    Abstract: Provided are compositions comprising fusion proteins, polynucleotides and/or expression vectors with therapeutic utility for suppressing and/or treating cancer, as well as medical uses of these agents, and methods of treatment in which they are used. A fusion protein of the invention comprises an amino acid sequence that provides the apoptosis-inducing activity of TRAIL, and a membrane-anchoring amino acid sequence. The amino acid sequence that provides the apoptosis-inducing activity of TRAIL comprises the extracellular domain of TRAIL, or a fragment or variant thereof. A fusion protein comprising an amino acid sequence from TRAIL that is able to induce apoptosis, and a second sequence that anchors the first sequence to the cell membrane, is markedly more effective at reducing viability of TRAIL receptor positive cells than the naturally occurring (“wild type”) TRAIL protein itself.
    Type: Grant
    Filed: April 15, 2015
    Date of Patent: August 6, 2019
    Assignee: The University of Liverpool
    Inventors: Daniel Palmer, Taha Elmitwalli
  • Patent number: 10358667
    Abstract: Embodiments of the disclosure provide for unique lipooligosaccharide/lipid A-based mimetics for use as adjuvants. Methods of generating lipooligosaccharide/lipid A-based mimetics are provided that utilize recombinantly engineered bacteria to produce the mimetics, including, for example, addition of one or more particular enzymes such as acyltransferases, deacylases, phosphatases, or glycosyltransferases.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: July 23, 2019
    Assignees: University of Maryland, Baltimore, University of Washington through its Center for Commercialization
    Inventors: Robert K. Ernst, Mark Pelletier, Adeline Hajjar
  • Patent number: 10351858
    Abstract: The present invention provides improved polysaccharides (e.g., gellan and diutan) produced by mutant gene N, M or I Sphingomonas strains containing at least one genetic modification that favors slime-forming polysaccharide production. Methods of making the mutant Sphingomonas strains and the culture broth containing such mutant Sphingomonas strains are also provided.
    Type: Grant
    Filed: November 13, 2017
    Date of Patent: July 16, 2019
    Assignee: CP Kelco U.S., Inc.
    Inventors: Nancy E. Harding, Yamini N. Patel, Russell J. Coleman
  • Patent number: 10351598
    Abstract: The present invention provides peptides with an anti-obesity and/or anti-diabetic activity consisting of an amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2, and optionally modified at their C- or N-terminal ends.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: July 16, 2019
    Assignee: CAREGEN CO., LTD.
    Inventors: Yong Ji Chung, Eun Mi Kim
  • Patent number: 10351617
    Abstract: Methods, compositions and kits for regulating complement activity or treating a complement activity disorder in a subject using soluble, membrane-independent CD59 protein, methods of assaying human macular degeneration (MD), and methods and kits for assaying potential therapeutic agents for treatment of human MD are provided herein.
    Type: Grant
    Filed: February 13, 2013
    Date of Patent: July 16, 2019
    Assignee: Trustees of Tufts College
    Inventors: Rajendra Kumar-Singh, Soibhan M. Cashman, Kasmir Ramo
  • Patent number: 10342829
    Abstract: The present invention relates to a new generation of chimeric antigen receptors (CAR) referred to as multi-chain CARs. Such CARs, which aim to redirect immune cell specificity and reactivity toward a selected target exploiting the ligand-binding domain properties, comprise separate extracellular ligand binding and signaling domains in different transmembrane polypeptides. 91The signaling domains are designed to assemble in juxtamembrane position, which forms flexible architecture closer to natural receptors, that confers optimal signal transduction. The invention encompasses the polynucleotides, vectors encoding said multi-chain CAR and the isolated cells expressing them at their surface, in particularly for their use in immunotherapy. The invention opens the way to efficient adoptive immunotherapy strategies for treating cancer and viral infections.
    Type: Grant
    Filed: September 4, 2013
    Date of Patent: July 9, 2019
    Assignee: CELLECTIS
    Inventors: Julianne Smith, Andrew Scharenberg, Cecile Mannioui, Justin Eyquem
  • Patent number: 10329541
    Abstract: The present invention relates to methods for the conversion of the substrate specificity of desaturases. Specifically, the present invention pertains to a method for the conversion of the substrate specificity of a ?5 and/or ?6 desaturase to the substrate specificity of a ?4 desaturase, the method comprising: identifying regions and/or amino acid residues which control the substrate specificity of (i) the ?5 and/or ?6 desaturase and (ii) the ?4 desaturase; and replacing in the amino acid sequence of the mentioned ?5 and/or ?6 desaturase, the regions and/or amino acid residues which control the substrate specificity of the ?5 and/or ?6 desaturase, by the corresponding regions and/or amino acid residues which control the substrate specificity of the ?4 desaturase, thereby converting the substrate specificity of the ?5 and/or ?6 desaturase to the substrate specificity of the ?4 desaturase.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: June 25, 2019
    Assignees: BASF PLANT SCIENCE COMPANY GMBH, BIORIGINAL FOOD & SCIENCE CORP.
    Inventors: Toralf Senger, Patricia Vrinten, Ze Long Lim
  • Patent number: 10322141
    Abstract: In certain aspects the invention provides immunogenic compositions comprising CH848 HIV-1 envelopes and their use in methods to induce immune responses in subjects, e.g., human subjects.
    Type: Grant
    Filed: March 31, 2015
    Date of Patent: June 18, 2019
    Assignees: DUKE UNIVERSITY, TRIAD NATIONAL SECURITY, LLC, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Barton F. Haynes, Beatrice H. Hahn, George M. Shaw, Bette T. Korber, Peter T. Hraber
  • Patent number: 10316337
    Abstract: The invention relates to a genetically engineered bacterium having an enzyme that converts 3-hydroxyisovaleryl-CoA to 3-hydroxyisovalerate and an enzyme that converts 3-hydroxyisovalerate to isobutylene. Typically, the bacterium is capable of producing isobutylene from a gaseous substrate containing CO, CO2, and/or H2, such as syngas or an industrial waste gas.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: June 11, 2019
    Assignee: LANZATECH NEW ZEALAND LIMITED
    Inventors: Michael Koepke, Rasmus Overgaard Jensen
  • Patent number: 10307356
    Abstract: Provided are: a method for producing a mycrosporine-like amino acid (MAA) that includes a step in which microbes are cultivated that produce MAA on the outside of bacterial cells, a step in which the bacterial cells and extracellular culture fluid are separated, and a step in which the MAA is recovered from the extracellular culture fluid; an MAA indicated by formula (1), an MAA produced using this method, or an ultraviolet-absorbing composition including the MAA indicated by formula (1); and a composition including the MAA produced using this method or the MAA indicated by formula (1), for preventing at least one symptom or disease selected from a group comprising acute skin reactions, aging of the skin, and skin cancer.
    Type: Grant
    Filed: May 12, 2015
    Date of Patent: June 4, 2019
    Assignees: THE KITASATO INSTITUTE, NAGASE & CO., LTD.
    Inventors: Haruo Ikeda, Shogo Yamamoto, Jun Matsumoto, Masahiro Sota
  • Patent number: 10306891
    Abstract: The present application relates to plant growth promoting microbes (PGPMs), compositions comprising these PGPMs and methods of using these PGPMs and/or compositions for enhancing plant health, plant growth and/or plant yield, and/or for preventing, inhibiting, or treating the development of plant pathogens or the development of phytopathogenic diseases. This application also provides non-naturally occurring plant varieties that are artificially infected with a PGPM descried herein, as well as seed, reproductive tissue, vegetative tissue, regenerative tissues, plant parts, or progeny thereof.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: June 4, 2019
    Inventors: Matthew N. Ashby, Christopher P. Belnap, Matthew Cornyn Kuchta, Victor Kunin, Caroline Kostecki, Ulrika Lidstrom, Natalia Shestakova, Ladonna Wood
  • Patent number: 10300115
    Abstract: The instant invention provides methods and compositions for modulation of the immune system. Specifically, the present disclosure provides methods and compositions for increasing T cell mediated immune response useful in the treatment of cancer and chronic infection.
    Type: Grant
    Filed: January 11, 2017
    Date of Patent: May 28, 2019
    Assignee: The United States of America, as represented by the Secretary, Department of Health & Human Services
    Inventors: Arya Biragyn, Kouji Matsushima, Dolgor Baatar
  • Patent number: 10302631
    Abstract: The present invention relates to a new optical tool for detecting and quantifying pyruvate in samples, in tissues and in cellular and subcellular compartments, with high spatial and temporal resolution, this is a Forster Resonance Energy Transfer (FRET)-based pyruvate sensor comprising a bacterial PdhR transcription factor between any suitable donor and acceptor fluorescent proteins moieties. The invention also relates to methods of use of this novel optical tool for the quantification of the activity of pyruvate transporters, for the quantification of the rates of cellular pyruvate production and consumption, and for the direct quantification of the rate of mitochondrial pyruvate consumption in intact cells.
    Type: Grant
    Filed: August 20, 2013
    Date of Patent: May 28, 2019
    Assignee: CENTRO DE ESTUDIOS CIENTIFICOS DE VALDIVIA
    Inventors: Luis Felipe Barros, Sebastian Ceballo, Alejandro San Martin
  • Patent number: 10301663
    Abstract: Methods for producing proteins, for example, recombinant meningococcal 2086 proteins, using fed-batch fermentation with continuous input of an inducer after achieving a threshold parameter, and continuous input of a carbon source, for example, a constant rate input, to improve protein yields, as well as high density protein compositions for use in the methods of the present invention, are provided.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: May 28, 2019
    Assignee: Wyeth, LLC
    Inventors: Wei-Qiang Willie Sun, Earl Joseph Pursell
  • Patent number: 10301356
    Abstract: The present invention described herein relates to the composition that interact with molecules that suppress the immune system.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: May 28, 2019
    Assignee: CANIMGUIDE THERAPEUTICS AB
    Inventor: Leif Håkansson
  • Patent number: 10301357
    Abstract: The present disclosure provides agents capable of promoting endogenous steroid production (such as endogenous testosterone production) without altering the endogenous luteinizing hormone. The present disclosure also provides associated therapeutic methods as well as screening assays for identifying further therapeutic agents for the prevention, treatment and/or alleviations of symptoms associated with hypogonadism.
    Type: Grant
    Filed: May 21, 2014
    Date of Patent: May 28, 2019
    Assignee: THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY
    Inventors: Vassilios Papadopoulos, Yasaman Aghazadeh, Jinjiang Fan
  • Patent number: 10293018
    Abstract: The present disclosure provides various molecular constructs having a targeting element and an effector element. Methods for treating various diseases using such molecular constructs are also disclosed.
    Type: Grant
    Filed: September 1, 2016
    Date of Patent: May 21, 2019
    Assignee: IMMUNWORK INC.
    Inventors: Tse-Wen Chang, Hsing-Mao Chu, Li-Yun Du
  • Patent number: 10280230
    Abstract: The invention relates to a method for producing a protein molecule composition having a defined glycosylation pattern, comprising (a) introducing in a host cell which is an immortalized human blood cell at least one nucleic acid encoding at least a part of said protein; and (b) culturing said host cell under conditions which permit the production of said protein molecule composition; and (c) isolating said protein molecule composition.
    Type: Grant
    Filed: May 4, 2015
    Date of Patent: May 7, 2019
    Assignee: Glycotope GmbH
    Inventors: Steffen Goletz, Antje Danielczyk, Hans Baumeister, Renate Stahn, Anja Loeffler, Lars Stoeckl
  • Patent number: 10273485
    Abstract: The present invention relates to a modified microorganism having, compared to its wild-type, a reduced activity of the enzyme that is encoded by the wcaJ-gene. The present invention also relates to a method for producing an organic compound and to the use of a modified microorganism.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: April 30, 2019
    Assignee: BASF SE
    Inventors: Joanna Martyna Krawczyk, Stefan Haefner, Hartwig Schröder, Esther Dantas Costa, Oskar Zelder, Gregory Von Abendroth, Christoph Wittmann, René Stellmacher, Judith Becker
  • Patent number: 10266835
    Abstract: This invention relates to the Agrobacterium bacterium to be used in plant transformation method comprising three types of plasmids. The Agrobacterium bacterium of this invention comprises plasmids of (1) to (3) shown below: (1) a plasmid comprising the following components: (i) the virB gene, the virC gene, the virD1 gene, the virD2 gene, the virD3 gene, the virG gene and the virJ gene of pTiBo542, and (ii) an origin of replication; (2) a disarmed Ti plasmid or a disarmed Ri plasmid of Agrobacterium bacterium; and (3) a plasmid having a T-DNA region consisting of a desired DNA; wherein each of the plasmids of (1) to (3) has a replication mechanism that enables a mutual coexistence with each other.
    Type: Grant
    Filed: March 27, 2014
    Date of Patent: April 23, 2019
    Assignee: JAPAN TOBACCO INC.
    Inventors: Teruyuki Imayama, Yukoh Hiei, Yuji Ishida
  • Patent number: 10266571
    Abstract: Antigenic polypeptides comprising linear immunodominant epitopes of Borrelia outer surface protein A (OspA) or Borrelia outer surface protein C (OspC) are useful as vaccines against Lyme disease, and as diagnostics for detecting Borrelia infections. The OspA and OspC antigenic polypeptides typically comprise a plurality of peptides representing epitope containing regions from multiple distinct phyletic groups. The antigenic polypeptides may also include epitopes from both Borrelia OspA and Borrelia OspC.
    Type: Grant
    Filed: November 25, 2016
    Date of Patent: April 23, 2019
    Assignee: VIRGINIA COMMONWEALTH UNIVERSITY
    Inventors: Christopher G. Earnhart, Richard T. Marconi
  • Patent number: 10266839
    Abstract: The present invention relates to a method for targeted inactivation of transcription factor using an artificial small interfering peptide and a use thereof. According to the present invention, an artificial small interfering peptide (a-siPEP) as a truncated from of the transcription factor for regulating transcription by dimerization was produced. It was also confirmed that, as a-siPEP forms a heterodimer with a transcription factor, DNA binding and transport into a nucleus of the transcription factor are inhibited, so that inactivation of the transcription factor is achieved at protein level. The method for inhibiting transcription factor activity using a-siPEP can replace a gene knock-out method and it allows protein-level inhibition of a transcription factor. Also, it is a transcription regulation method with high precision and high efficiency that can be applied for both monocot and dicot plants.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: April 23, 2019
    Assignee: SNU R&DB FOUNDATION
    Inventors: Chung Mo Park, Pil Joon Seo
  • Patent number: 10266859
    Abstract: 5-hydroxytryptophan (5-HTP), a precursor of serotonin, is produced in a microbial host cell. A modified bacterial phenylalanine 4-hydroxylase (P4H) catalyzes the tryptophan 5-hydroxylation reaction. Optionally the host cell includes a cofactor regeneration mechanism, allowing continuous production of 5-HTP without supplementation of exogenous cofactors.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: April 23, 2019
    Assignee: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.
    Inventors: Yajun Yan, Yuheng Lin
  • Patent number: 10258557
    Abstract: A synthetic peptide for stimulating melanogenesis is provided. The synthetic peptide consists of the amino acid sequence of AsnSerAlaThrGluArgGlu (SEQ ID NO: 1). Also provided are methods and compositions for stimulating melanogenesis in a subject.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: April 16, 2019
    Inventor: Yu-Chun Liu
  • Patent number: 10258669
    Abstract: A group of polypeptides and a complex formed by the polypeptides and human serum albumin, a method for improving the solubility of the group of polypeptides in a salt solution by combining the polypeptides with human serum albumin, a method for preparing the complex formed by the group of polypeptides and human serum albumin, and an application of the group of polypeptides and the complex formed by the polypeptides and human serum albumin in the preparation of drugs for suppressing tumor metastasis and treating leukemia are described.
    Type: Grant
    Filed: July 1, 2015
    Date of Patent: April 16, 2019
    Assignees: National Center for Nanoscience and Technology, China, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences
    Inventors: Chen Wang, Hongyang Duan, Yanlian Yang, Haiyan Xu, Xiaojin Li, Hua Guo, Hanyi Xie, Yue Yu
  • Patent number: 10253302
    Abstract: A method for producing an ordered protein lattice, the method comprising: (a) providing a first component comprising a subunit of a homooligomeric protein assembly fused to a first subunit of a heterooligomeric protein assembly, and a second component comprising a second subunit of the heterooligomeric protein assembly, wherein the homooligomeric protein assembly and the heterooligomeric protein assembly are each symmetrical in two or three dimensions and share a rotational symmetry axis of the same order; (b) mixing said first monomer and said second monomer to produce a mixture; and (c1) (i) heating the mixture to a temperature about 2° C. to about 10° C. below the visible dissociation temperature; (ii) cooling the mixture by about 10° C. to about 20° C.; and (iii) repeating steps (i) and (ii) at least 10 times; or (c2) (i) heating the mixture to a temperature about 2° C. to about 30° C. or more below the visible dissociation temperature; and (ii) holding the mixture at a temperature about 2° C.
    Type: Grant
    Filed: August 21, 2014
    Date of Patent: April 9, 2019
    Assignee: Crysalin Ltd.
    Inventors: John Charles Sinclair, Ceri John Lewis
  • Patent number: 10251928
    Abstract: The present disclosure relates to nutritional supplement including a peptide component. The nutritional supplement further includes a source of long-chain polyunsaturated fatty acids and Lactobacillus rhamnosus GG. The disclosure further relates to methods of protecting against obesity and its related metabolic disorders and inflammatory diseases in a target subject by providing the nutritional supplement(s) disclosed herein to a target subject, which includes a pediatric subject.
    Type: Grant
    Filed: November 6, 2014
    Date of Patent: April 9, 2019
    Assignee: MEAD JOHNSON NUTRITION COMPANY
    Inventors: Eric A. F. van Tol, Marieke H. Schoemaker, Gabriele Gross, Teartse Tim Lambers, Peter Wielinga, Robert Kleemann
  • Patent number: 10245309
    Abstract: The invention provides peptide vaccines comprising the signal peptide domain of selected target antigens of intracellular pathogens. The peptide vaccines of the invention contain multiple class II and class I-restricted epitopes and are recognized and presented by the majority of the vaccinated human population. The invention provides in particular anti tuberculosis vaccines. The invention further provides compositions comprising the vaccines as well as their use to treat or prevent infection.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: April 2, 2019
    Assignees: VAXIL BIOTHERAPEUTICS LTD.
    Inventor: Lior Carmon
  • Patent number: 10233468
    Abstract: An object of the present invention is to provide a microorganism strain that accumulates a high molecular weight PHA, and a PHA production method using the microorganism. The present invention provides a method for producing a PHA copolymer, which includes culturing a microorganism, wherein at least a portion of either of the following genes (a) and (b) of the microorganism has been altered by substitution, deletion, insertion, and/or addition to reduce or eliminate the activity of a PHA degrading enzyme encoded by the gene: (a) a PHA degrading enzyme gene encoding the amino acid sequence of SEQ ID NO:2 in the sequence listing; and (b) a gene encoding a polypeptide having at least 85% sequence identity to the amino acid sequence of SEQ ID NO:2 in the sequence listing and having PHA degrading enzyme activity.
    Type: Grant
    Filed: October 22, 2013
    Date of Patent: March 19, 2019
    Assignee: KANEKA CORPORATION
    Inventors: Hisashi Arikawa, Shunsuke Sato, Keiji Matsumoto
  • Patent number: 10227665
    Abstract: A method for identifying a risk factor for diseases, disorders or conditions, such as those caused by human immunodeficiency virus, using the polymerase chain reaction and specific primers. Methods for treating patients having these diseases, disorders or conditions by antimicrobial treatment of the risk factor by combined antiviral and antibacterial treatment or by sustaining or stimulating the subject's immune system. Methods for screening biological products including red blood cell preparations. Primers and methods for detecting nucleic acids or microbial agents associated with red blood cells, such as those associated with red blood cells in subjects infected with HIV and undergoing antiretroviral therapy.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: March 12, 2019
    Inventor: Luc Montagnier
  • Patent number: 10226528
    Abstract: Disclosed herein is a vaccine comprising an antigen and one or more bimolecular adjuvant. Also disclosed herein are methods for increasing an immune response in a subject. The methods may comprise administering the vaccine to the subject in need thereof.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: March 12, 2019
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: David B. Weiner, Karuppiah Muthumani
  • Patent number: 10229112
    Abstract: A system for determining a similarity between a name phrase and a comparison name phrase, for each name in the name phrase, scores the name. The scoring is based on the field frequency of the name in a name database, where the field frequency indicates a given name frequency and/or a surname frequency in the database. The system uses the scoring to determine a transition from a given name to a surname in the name phrase. The system determines a primary given name and a primary surname in the name phrase based on the scoring and the transition. The system uses the primary given name and primary surname to determine a similarity between the name phrase and a comparison name phrase, where the comparison name phrase comprises a comparison given name and a comparison surname.
    Type: Grant
    Filed: March 7, 2016
    Date of Patent: March 12, 2019
    Assignee: International Business Machines Corporation
    Inventor: Frankie E. Patman Maguire
  • Patent number: 10221249
    Abstract: The present disclosure relates to therapies for the treatment of tumor, autoimmune diseases, or other diseases. In some embodiments, the present disclosure can relate to subject-specific selection of humanized antibodies targeting clonal lineage specific marker proteins.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: March 5, 2019
    Assignee: Affigen, LLC
    Inventors: David J. States, Carlos F. Santos
  • Patent number: 10221226
    Abstract: LEDGF peptides with anti-protein aggregation activity and methods of use are provided. The LEDGF peptides disclosed herein demonstrate an ability to treat degenerative diseases and diseases with various cellular stresses including oxidative stress and protein-aggregation stress. In addition, extended release formulations, including formulations suitable for ophthalmic administration are provided.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: March 5, 2019
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventors: Uday B. Kompella, Rinku Baid, Arun K. Upadhyay, Sarath Yandrapu
  • Patent number: 10215975
    Abstract: Some embodiments of the invention include a system comprising a positioning device configured to a hold a sample and adjust a position of a sample in response to receiving a drift compensation signal; a first light source disposed to transilluminate the sample; a second light source disposed to epi-illuminate the sample; an optical system configured to receive light from the sample and generate a three-dimensional point spread function from the light from the sample; an image sensor disposed relative to the optical system that produces an image from the light collected from the sample via the optical system; and logic electrically coupled with the image detector and the positioning device, the logic configured to determine one or more drift compensation values from images imaged by the image detector, and configured to send one or more drift compensation signals to the positioning device.
    Type: Grant
    Filed: February 8, 2016
    Date of Patent: February 26, 2019
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventors: Rafael Piestun, Wyatt Mohrman, Ginni Grover
  • Patent number: 10208092
    Abstract: The invention discloses kappa light chain-binding polypeptide comprising a mutated binding domain of Peptostreptococcus protein L, wherein at least one asparagine residue of a parental domain defined by, or having at least 95% or 98% sequence homology with, SEQ ID NO: 2-6 or 2 has been mutated to another amino acid residue which is not asparagine, proline or cysteine.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: February 19, 2019
    Assignee: GE Healthcare Bio-Process R&D AB
    Inventors: Gustav Rodrigo, Mats Ander, Tomas Bjorkman
  • Patent number: 10208125
    Abstract: This disclosure provides anti-MUC1 binding agents (e.g., antibodies and chimeric antigen receptors) and methods of treatment, prophylaxis, detection, and diagnosis using the same.
    Type: Grant
    Filed: July 14, 2014
    Date of Patent: February 19, 2019
    Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education, Bluefin BioMedicine, Inc.
    Inventors: Robert E. Schoen, Olivera J. Finn, Shuji Sato, Wan Cheung Cheung, Roberto D. Polakiewicz
  • Patent number: 10208326
    Abstract: The invention relates to recombinant microorganisms and methods for producing manoyl oxide.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: February 19, 2019
    Assignee: EVOLVA SA
    Inventor: Niels Bjerg Jensen
  • Patent number: 10188114
    Abstract: It can be useful to regulate the growth of microbial cells. Some embodiments herein provide genetically engineered microbial cells that can produce bacteriocins to control the growth of microbial cells. In some embodiments, microbial cells are contained within a desired environment. In some embodiments, contaminating microbial cells are neutralized. In some embodiments, a first microbial cell type regulates the growth of a second microbial cell type so as to maintain a desired ratio of the two cell types.
    Type: Grant
    Filed: March 31, 2016
    Date of Patent: January 29, 2019
    Assignee: SYNGULON SA
    Inventor: Philippe Gabant
  • Patent number: 10155785
    Abstract: The present invention provides, among other things, methods of purifying messenger RNA (mRNA) including the steps of (a) precipitating mRNA from an impure preparation; (b) subjecting the impure preparation comprising precipitated mRNA to a purification process involving membrane filtration such that the precipitated mRNA is captured by a membrane; and (c) eluting the captured precipitated mRNA from the membrane by re-solubilizing the mRNA, thereby resulting in a purified mRNA solution. In some embodiments, a purification process involving membrane filtration suitable for the present invention is tangential flow filtration.
    Type: Grant
    Filed: December 4, 2017
    Date of Patent: December 18, 2018
    Assignee: Translate Bio, Inc.
    Inventors: Frank DeRosa, Anusha Dias, Shrirang Karve, Michael Heartlein
  • Patent number: 10155933
    Abstract: An isolated microorganism that expresses enzymes of the reductive glycine pathway is disclosed. The microorganism is capable of converting formate to pyruvate or glycerate via the formation of glycine and serine. Methods of generating same are further described.
    Type: Grant
    Filed: July 29, 2013
    Date of Patent: December 18, 2018
    Assignee: Yeda Research and Development Co., Ltd.
    Inventors: Arren Bar-Even, Ron Milo, Elad Noor, Oren Yishai
  • Patent number: 10138444
    Abstract: A bacteria referred to here as Bacillus subtilis 6A-1 is provided, compositions thereof and processes for use of the bacteria, spores, cells, extracts and enzymes. The compositions which comprise the bacteria, spores, cells, extracts and/or enzymes are capable of degrading polysaccharides. Such compositions are capable of degrading cellulose, including plant-produced cellulose, microcrystalline cellulose and carboxymethyl cellulose. The bacteria produces at least two cellulose-degrading protein fractions. Cellulose degrading activity continues across pH2 to pH13.
    Type: Grant
    Filed: September 12, 2016
    Date of Patent: November 27, 2018
    Assignee: Agri-King, Inc.
    Inventors: Gbenga Ayangbile, Mary Grzemski, James F. Tobey, Jr., David Spangler, Lucas Krueger
  • Patent number: 10138461
    Abstract: The present invention relates to animal protein-free cell culture media comprising polyamines and a plant- and/or yeast-derived hydrolysate. The invention also relates to animal protein-free culturing processes, wherein cells can be cultivated, propagated and passaged without adding supplementary animal proteins in the culture medium. These processes are useful in cultivating cells, such as recombinant cells or cells infected with a virus, and for producing biological products by cell culture processes.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: November 27, 2018
    Assignees: Baxalta Gmbh, Baxalta Incorporated
    Inventors: Leopold Grillberger, Manfred Reiter, Wolfgang Mundt, Friedrich Dorner
  • Patent number: 10137175
    Abstract: The application relates to antimicrobial agents against Gram-negative bacteria, in particular to fusion proteins composed of an enzyme having the activity of degrading the cell wall of Gram-negative bacteria and a peptide stretch fused to the enzyme at the N- or C-terminus, as well as pharmaceutical compositions comprising the same. Moreover, it relates to nucleic acid molecules encoding such a fusion protein, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, it relates to such a fusion protein for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means or as cosmetic substance. The application also relates to the treatment or prevention of Gram-negative bacterial contamination of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: November 27, 2018
    Assignees: LYSANDO AG, KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D
    Inventors: Rob Lavigne, Stefan Miller, Yves Briers, Guido Volckaert, Maarten Walmagh
  • Patent number: 10131884
    Abstract: The invention provides a recombinant, acetogenic bacterium that consumes a substrate comprising CH4 and converts at least a portion of the CH4 to a product. In particular, the bacterium of may comprise one or more of exogenous methane monooxygenase (MMO), exogenous nitrite reductase (NIR), and exogenous nitric oxide dismutase (NOD). The invention further provides a method for producing a product comprising providing a substrate comprising CH4 to a culture comprising a recombinant, acetogenic bacterium, whereby the bacterium converts at least a portion of the CH4 to a product.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: November 20, 2018
    Assignee: LANZATECH NEW ZEALAND LIMITED
    Inventors: Michael Koepke, Peter Dürre
  • Patent number: 10117908
    Abstract: The present disclosure relates to suppression of cellular transformation and dysplasia by topical application of Lefty. In particular, the present disclosure provides compositions and methods for topically applying Lefty to treat and prevent cancers.
    Type: Grant
    Filed: October 17, 2014
    Date of Patent: November 6, 2018
    Assignee: GRANT LABS, INC.
    Inventor: Charles E. Craft
  • Patent number: 10111945
    Abstract: Provided herein are genetically modified arenaviral vectors suitable as vaccines for prevention and treatment of cytomegalovirus infections and reactivation. Also provided herein are pharmaceutical compositions and methods for the treatment of cytomegalovirus infections and reactivation. Specifically, provided herein are pharmaceutical compositions, vaccines, and methods of treating cytomegalovirus infections and reactivation.
    Type: Grant
    Filed: December 3, 2014
    Date of Patent: October 30, 2018
    Assignee: Hookipa Biotech GmbH
    Inventors: Klaus Orlinger, Karen Lingnau, Thomas Monath, Farshad Guirakhoo, Gerhard Fuhrmann, Katherine Cohen, Vera Baumgartl-Strasser, Andreas Aspöck, Manuela Kainer, Bernhard Brim, Bettina Kiefmann, Elizabeth Watson, Mario Aistleithner, Katharina Bayer, Elsa Mühlbacher
  • Patent number: 10105412
    Abstract: Streptococcus pneumoniae is a major health concern, especially in very young, elderly, or immunocompromised patients. The present disclosure provides, inter alia, certain highly effective vaccines and pharmaceutical compositions in Streptococcus pneumoniae. The antigens may be used therapeutically or prophylactically.
    Type: Grant
    Filed: June 29, 2010
    Date of Patent: October 23, 2018
    Assignees: Genocea Biosciences, Inc., Chidlren's Medical Center Corporation
    Inventors: Todd Gierahn, Richard Malley